Dr. Dandan Dong is the Chief Business Officer of ArriVent Biopharma. Dr. Dong has more than 15 years’ experience in global healthcare investment. Before joining ArriVent, Dr. Dong was the Managing Director of Vivo Capital, and the General Partner of Vivo Capital PANDA Fund & Innovation Fund II. Over her career she has led multiple successful investments in innovative drugs in both the U.S. and Greater China Market. She has been focusing on cross border opportunities, incubated multiple biotech companies with cross border theses. Most recently, she was the Chief Business Officer, Executive Board member of Visen Pharmaceutical, a joint venture between Ascendis Pharma (NASDAQ: ASND). As a founding member, she led the effort of in-licensing core pipelines, designing corporate strategy, recruiting key management, financing and was the chair of Joint Collaboration Committee. She co-founded RareStone Group, to build the first rare disease ecosystem in the Greater China, served on the board, the transaction committee and financing committee. Dr. Dong holds a Ph.D. in biomedical science from Fudan University and she completed the Pre-doctoral Fellowship program at New York University School of Medicine.